Cosmetic cross-reference

Uric Acid

CAS 69-93-2

Uric Acid (CAS 69-93-2) is a Phase 2 pharmaceutical compound with 2 bioactivity targets and 36 adverse event associations.

SOURCE NLM DailyMed

Label records

0

SOURCE EMBL-EBI ChEMBL

Bioactivity

2

SOURCE DrugCentral

Adverse signals

36

SOURCE IUPHAR/BPS

PubMed IDs

1

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Uric Acid

CAS Number

69-93-2

UNII

268B43MJ25

InChIKey

LEHOTFFKMJEONL-UHFFFAOYSA-N

ChEMBL ID

CHEMBL792

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL792 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	489000 nM	4	-
-	Ki	4340 nM	1	-

SOURCE PharmGKB 3 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

PADI4 (PA32903) rs2477134

Allele G is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.

Evidence: -; PMID 29580174

VEGFC (PA37304) rs1002976

Allele C is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T.

Evidence: -; PMID 29580174

BRINP3 (PA142671896) rs950569

Allele T is associated with increased concentrations of uric acid in people with Hypertension as compared to allele G.

Evidence: -; PMID 29580174

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Uric Acid used for in pharmaceutical contexts?

Uric Acid (CAS 69-93-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Uric Acid?

Uric Acid has 36 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal discomfort, Abdominal pain upper, Asthenia, Blood creatinine increased, Blood pressure decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Uric Acid also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Uric Acid with EU status "permitted".

What clinical phase is Uric Acid in?

Uric Acid is rendered with ChEMBL max phase 2.